BRIEF-FDA grants priority review of Xarelto SNDA to reduce risk of recurrent VTE
June 28, 2017 at 08:51 AM EDT
* U.S. FDA grants priority review of Xarelto® (rivaroxaban) SNDA for a 10 mg dose to reduce the risk of recurrent venous thromboembolism (VTE)
